Big Pharma At It Again: Disease Mongering for Profit

The Most Revolutionary Act

big pharma

As shameless as ever, Big Pharma is aggressively medicalizing the problems of living as they pursue obscene profits. Their latest disease mongering campaign, promoting the drug Flibanserin, is aimed at women. Like cancer causing Premarin, hyped for its ability to slow aging, and Sarafem (recently linked to birth defects), hyped for its effectiveness in industry-created “premenstrual dysphoric disorder”.

Originally developed by Boehringer Ingelheim, this new drug has been acquired by Sprout Pharmaceuticals, a company launched in 2011 to develop products for female sexual health (i.e. to cash in on the $1.5 billion Viagra market). It allegedly treats “low sexual arousal disorder” in women.

Taken Everyday, Potentially for Years

Last week the Telegraph reported that two key FDA advisory committees are recommending approval of Flibanserin, also known as “pink Viagra.” Despite its nickname, Flibanserin is nothing like Viagra. While a man only takes Viagra when he wants to have…

View original post 577 more words

3 thoughts on “Big Pharma At It Again: Disease Mongering for Profit

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s